DOUGLAS CALLAHAN: Open Payments
NPI 1265540355 · ST GEORGE, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,583 in 85 payments from 25 companies in 2025. Trend: 2023 $1,393 · 2024 $1,496 · 2025 $1,583
Food & beverage: $1,583
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $383 |
| AstraZeneca Pharmaceuticals LP | 8 | $173 |
| PFIZER INC. | 6 | $112 |
| Aimmune Therapeutics, Inc. | 6 | $104 |
| Boston Scientific Corporation | 4 | $85 |
| Otsuka America Pharmaceutical, Inc. | 4 | $85 |
| Lilly USA, LLC | 4 | $71 |
| Teva Pharmaceuticals USA, Inc. | 2 | $55 |
| Novartis Pharmaceuticals Corporation | 2 | $49 |
| Amgen Inc. | 2 | $47 |
Products named: UBRELVY, QULIPTA, REXULTI, ZENPEP, VRAYLAR, FARXIGA, General - Pain Management, NURTEC ODT.
Industry payments across UT — which companies pay providers there.
